Metabolic
PRECLINICAL NO FDA APPROVAL
AOD-9604
Fat mobilization support
AOD-9604 is a synthetic fragment of human growth hormone (amino acids 177–191, with an N-terminal tyrosine) that targets fat metabolism without causing muscle growth or disrupting insulin. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis via beta-3 adrenergic receptors, without elevating IGF-1. In trials, obese participants lost ~5.7 lb over 12 weeks with diet and exercise; the Phase IIb obesity result was only ~2% vs placebo, so it's best understood as a "fat mobilizer" / fine-tuning tool for already-lean individuals, not a primary appetite suppressant like GLP-1s. Dosed 300 mcg SubQ daily (range 250–500 mcg).
MECHANISM
Lipolysis signaling via GH fragment
BENEFITS
Fat mobilization, Gentle cut support, No hyperglycemia
TYPICAL DOSE
250-500 mcg
CYCLE LENGTH
6-12 weeks
FREQUENCY
Daily (AM fasted)
At a Glance
Dosage | 300 mcg subcutaneous daily (range 250–500 mcg). |
Protocol | 12–16 weeks on, 4 weeks off. Morning fasted, 30–60 min before activity to ensure mobilized fat gets oxidized. |
Results timeline | If no measurable change by week 4, the problem is elsewhere — a marginal optimizer for already-lean individuals, not a primary fat-loss driver. |
Side effects | Indistinguishable from placebo across six RCTs — no IGF-1 elevation, no glucose disruption, no antibody formation. |
Regulatory status | Phase IIb failed for obesity (~2% vs placebo); discontinued 2007. Not FDA-approved (has FDA GRAS food-ingredient status). WADA prohibited. |
Best stacked with | Tesamorelin (anabolic protection during cuts); MOTS-c, L-Carnitine (Morning Partition Stack). |
AOD-9604 failed Phase 3 trials in 2007 — dropped by Metabolic Pharmaceuticals after a ~2% effect vs placebo in severely obese patients. The failure was real, but the logic behind continued niche use holds: a drug that doesn't move the needle for morbid obesity can still matter for someone already lean chasing the last 2–3%. It is the lipolytic fragment of HGH, separated from the growth-promoting region — activating beta-3 receptors in fat tissue without elevating IGF-1, disrupting glucose, or causing edema. That specificity is also its ceiling: a layer-five fine-tuning tool, after diet, training, sleep, and a primary compound are dialed in.
What Is AOD-9604?
A synthetic peptide of HGH amino acids 177–191 (C-terminal region) plus an N-terminal tyrosine for stability. "AOD" = Advanced Obesity Drug; "9604" was its Metabolic Pharmaceuticals development code (Australia, 1990s). The tyrosine modification prevents residual HGH-like effects on IGF-1 or growth — so it isolates the fat-mobilization signal without the hormonal complexity.
How AOD-9604 Works: The Beta-3 Receptor Story
AOD-9604 binds fat cells and upregulates beta-3 adrenergic receptors, making them more responsive to catecholamines (epinephrine/norepinephrine). This increases hormone-sensitive lipase activity, releasing stored triglycerides as free fatty acids.
Knockout study: a 2001 Heffernan mouse study showed normal obese mice had significant fat reduction while beta-3-receptor knockout mice showed no response — proving the effect is entirely beta-3-dependent. Human beta-3 expression varies, which may explain variable responses.
Mobilization ≠ oxidation: released fatty acids must be burned, or they re-esterify and return to storage. AOD-9604 opens the door; activity burns what comes out — which is why timing with activity matters.
The Phase IIb Reality
The OPTIONS trial (534 obese adults, 24 weeks) produced ~2% body-weight reduction vs placebo — below the FDA threshold for an obesity drug — and development was discontinued in 2007. For context, modern GLP-1s deliver ~15% (semaglutide), ~21% (tirzepatide), ~24% (retatrutide in trials). But a failed obesity drug isn't a useless compound: for someone at 12% body fat seeking 10%, a small lipolytic bias layered onto optimized training, nutrition, GLP-1, tesamorelin, and activity may provide the final push.
Exceptional safety: across six randomized double-blind placebo-controlled trials (Stier et al.):
Safety parameter | Result |
IGF-1 elevation | None detected |
Glucose metabolism (OGTT) | No negative effect |
Anti-AOD9604 antibodies | None detected |
Overall tolerability | Indistinguishable from placebo |
Who Should Consider AOD-9604
Good candidates: already lean (sub-15% men / sub-22% women); training 3–4×/week; nutrition dialed; higher-leverage tools optimized; willing to pair with activity; realistic (2–3%) expectations. Not good candidates: obese/overweight (use GLP-1s); expecting dramatic results; skipping fundamentals; unwilling to pair with tesamorelin; seeking a primary tool; competitive athletes (WADA-prohibited).
Layer | Intervention | Effect size |
1 | Nutrition (deficit) | Massive |
2 | Training | Large |
3 | GLP-1 agonists | Large |
4 | Tesamorelin | Moderate |
5 | AOD-9604 | Small |
Dosing Protocol
Dose | 300 mcg daily (range 250–500 mcg) |
Timing | AM fasted, 30–60 min before activity |
Route | Subcutaneous (abdomen preferred, rotate quadrants) |
Cycle | 12–16 weeks on, 4 weeks off |
Evaluation | If no change by week 4, the problem is elsewhere |
Morning fasted + activity: wake fasted → inject 300 mcg SubQ → wait 30–60 min → Zone-2 cardio/training → mobilized fatty acids get burned rather than re-stored. Reconstitute with bacteriostatic water, refrigerate, use within 4–6 weeks; see the reconstitution guide. Inject into abdominal fat (rotate quadrants, 2+ inches from navel); 29–31 gauge insulin syringe.
Stacking Protocols
Morning Partition Stack (fasted): AOD-9604 300 mcg SC (mobilizes fat), L-Carnitine 500 mg IM (shuttles fat into mitochondria), MOTS-c 5–10 mg SC (programs mitochondria to prefer fat) → then 30–60 min Zone-2 cardio. Complete cutting protocol: add evening Tesamorelin 1–2 mg SC (anabolic protection), weekly GLP-1 agonist, resistance training 3–4×/week, protein 1.6–2.2 g/kg. Tesamorelin is required because AOD provides zero muscle protection.
AOD-9604 vs Tesamorelin
Property | AOD-9604 | Tesamorelin |
What it is | HGH fragment 177-191 (lipolytic domain) | Full GHRH(1-44) analog |
Mechanism | Beta-3 receptor activation on fat cells | Restores pulsatile GH secretion |
IGF-1 effect | None | Elevates (requires monitoring) |
Muscle protection | None | Yes — nitrogen retention |
Fat targeting | General lipolysis (needs activity) | Visceral fat (15–20% VAT reduction) |
Clinical evidence | Phase IIb failed (~2% vs placebo) | FDA-approved; multiple positive RCTs |
Role | Optional fine-tuning (layer 5) | Core anabolic protection (layer 4) |
If you can only choose one, choose tesamorelin. Running both: tesamorelin at night, AOD in the morning.
Side Effects and Safety
Occasional injection-site reactions and headache; rare nausea/GI upset. Notably does NOT cause IGF-1 elevation, glucose disruption, edema, carpal tunnel, antibody formation, or pituitary suppression. Received FDA GRAS (Generally Recognized As Safe) status as a food ingredient in 2019 — not therapeutic approval, but a reinforcing safety signal. WADA-prohibited under S2 (Peptide Hormones, Growth Factors) due to its HGH-fragment origin.
FAQ
Does AOD-9604 actually work?
Mechanistically yes (beta-3 activation, lipolysis); clinically the effect is modest (~2% in trials). For already-lean individuals with fundamentals optimized, the marginal lipolytic bias may help stubborn areas. For significant fat loss, GLP-1 agonists are far more effective.
What is the recommended dosage and protocol?
300 mcg SubQ daily in the abdomen, morning fasted, 30–60 min before activity (range 250–500 mcg; higher isn't proportionally better). Cycles ~8 weeks on, 4 weeks off. Must be paired with activity to oxidize mobilized fat.
Does AOD-9604 need to be cycled?
Typically 8-week courses with 4-week breaks, though cycling is less critical since it doesn't affect IGF-1 or hormonal axes. Breaks are mostly for honest assessment.
How long until I see results?
Subtle effects over 4–8 weeks, not dramatic transformation. Don't expect semaglutide-level changes.
What are the side effects?
Occasional injection-site reactions and headaches, rare nausea. Does NOT elevate IGF-1, disrupt glucose, cause edema, or cause carpal tunnel — one of the safest peptides available.
Can I take AOD-9604 with GLP-1 medications?
Yes — entirely different mechanisms (beta-3 vs GIP/GLP-1), no interaction. GLP-1 does the heavy lifting; AOD adds a marginal lipolytic signal for stubborn areas. GLP-1 weekly, AOD daily AM fasted.
How do I store AOD-9604?
Powder: refrigerate or freeze. Reconstituted: refrigerate (2–8°C), use within 4–6 weeks; protect from light/temperature swings.
Is AOD-9604 the same as HGH fragment?
It's the 177–191 lipolytic fragment of HGH, modified with a tyrosine to prevent IGF-1/growth effects — derived from HGH but engineered to isolate only fat mobilization.
Is AOD-9604 banned in sports?
Yes — WADA prohibits it under peptide hormones/growth factors due to its HGH-fragment origin, despite minimal performance enhancement.
Why pair AOD-9604 with tesamorelin?
AOD provides zero muscle protection; tesamorelin restores GH pulsatility for anabolic support. Using AOD alone during a deficit risks disproportionate lean-mass loss.
Related Topics
Tesamorelin Guide — GH-axis support with muscle preservation
Semaglutide Guide — primary fat-loss tool
Tirzepatide Guide — better body-composition data
MOTS-c Guide — mitochondrial support for the morning stack
L-Carnitine — fatty-acid transport in the morning stack
Reconstitution Guide — peptide preparation
Retatrutide Guide — triple-agonist; AOD-9604 as an adjunct for stubborn areas
References
Heffernan M, Summers RJ, Thorburn A, et al. Effects of HGH and its lipolytic fragment (AOD9604) on lipid metabolism — beta-3-AR knockout. Endocrinology 2001;142(12):5182-5189. PMID 11713213. DOI
Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab 2013;3(1-2):7-15. DOI
Ng FM, Sun J, Sharma L, et al. Metabolic effects of AOD9604 on obese Zucker rats. J Mol Endocrinol 2000;25(3):287-294. PMID 11146367. DOI
Cox HD, Rampton J, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal 2015;7(1):31-38. PMID 25208511. DOI
Valentino MA, Lin JE, Snook AE, et al. Central and peripheral molecular targets for anti-obesity pharmacotherapy. Clin Pharmacol Ther 2010;87(6):652-662. DOI
Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs 2004;5(4):431-437. PMID 15134286.
AOD9604 overview. Wikipedia
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.